Format

Send to

Choose Destination
See comment in PubMed Commons below
Front Biosci. 2007 Sep 1;12:4957-71.

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.

Author information

1
Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Abstract

Prostate cancer is the most common non-cutaneous malignancy in American men. Standard therapeutic strategies for systemic disease include androgen-deprivation therapy (ADT) and chemotherapy, both of which are palliative. However, there is a growing interest in the use of immunotherapy for prostate cancer. Evidence suggests that ADT may 1) enhance lymphopoiesis and thus potentially improve immune responses to vaccine, 2) renew thymopoiesis and thus reverse age-induced thymic involution, 3) augment B-cell development, and 4) mitigate tolerance to prostate cancer antigens. Although no vaccines are currently approved for prostate cancer, there are many promising agents under investigation. This review focuses on recent findings on immune regulation by androgens and immune-system regeneration with ADT, with emphasis on the rationale for the combination of ADT and vaccines in the clinical treatment of prostate cancer.

PMID:
17569623
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Frontiers in Bioscience
    Loading ...
    Support Center